## Diagnosis: Warm Autoimmune Hemolytic Anemia (AIHA) ### Clinical Presentation The patient presents with hemolytic anemia (low Hb, elevated reticulocyte count, indirect hyperbilirubinemia) and a positive DAT, confirming immune-mediated hemolysis. The absence of transfusion or pregnancy history excludes secondary causes. ### Drug of Choice: Corticosteroids **Key Point:** Corticosteroids (Prednisolone 1 mg/kg/day) are the first-line pharmacological treatment for warm AIHA. They suppress antibody production and reduce complement-mediated destruction of RBCs. **High-Yield:** Response rates to corticosteroids in warm AIHA are 70–80%, with most patients achieving remission within 2–4 weeks. ### Treatment Algorithm ```mermaid flowchart TD A[Warm AIHA diagnosed] --> B[Corticosteroids first-line] B --> C{Response at 2-4 weeks?} C -->|Yes| D[Taper and maintain] C -->|No| E[Add second-line agent] E --> F[Rituximab or Azathioprine] G[Splenectomy] --> H[Reserved for steroid-dependent/refractory cases] ``` ### Comparison of Treatment Options | Agent | Role | Timing | Efficacy | |-------|------|--------|----------| | **Corticosteroids** | First-line | Immediate | 70–80% response | | Rituximab | Second-line (refractory) | Weeks 2–4 | 50–60% response | | Azathioprine | Steroid-sparing agent | Weeks 4–8 | Adjunctive | | Splenectomy | Refractory/steroid-dependent | After medical failure | 50–60% durable remission | **Clinical Pearl:** Splenectomy is NOT first-line; it is reserved for patients who fail corticosteroids or become steroid-dependent. Rituximab is increasingly used as second-line therapy in refractory cases. **Tip:** In NEET PG, when a warm AIHA patient is presented without mention of steroid failure or refractoriness, always choose corticosteroids as the answer.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.